STOCK TITAN

Phibro Animal Health Corporation (PAHC) Stock News, May-Nov 2025

PAHC NASDAQ

Phibro Animal Health Corporation reports developments in animal health, mineral nutrition and performance products for food-animal markets. The company develops, manufactures and markets antibacterials, anticoccidials, nutritional specialty products, vaccines and mineral nutrition products for poultry, swine, beef and dairy cattle, and aquaculture in the United States and international markets.

Recurring PAHC news includes quarterly results and guidance, cash dividend declarations on Class A and Class B common stock, investor conference participation and regulatory updates affecting antimicrobial products such as virginiamycin and bacitracin. Company updates also address product portfolio activity, acquisition-related effects, input and distribution costs, foreign-currency impacts and tools such as PhibroVet for veterinary prescription management.

Rhea-AI Summary

Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both Class A and Class B common stock. The dividend is payable on December 17, 2025 to stockholders of record at the close of business on November 26, 2025. The declaration was made by the Board of Directors in Teaneck, NJ.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.28%
Tags
dividends
-
Rhea-AI Summary

Phibro Animal Health (NASDAQ:PAHC) announced the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease on October 30, 2025. Restoris, developed with a U.S. dental school and licensed to Phibro, is applied into periodontal pockets, cured with supplied UV light, and uses piezoelectric particles to generate microcurrents that stimulate osteoblasts.

Clinical and laboratory studies showed significant reductions in periodontal pocket depth and generation of alveolar bone around the treated tooth within 30 days. Restoris is available for pre-order from Patterson Veterinary Supply and will ship within the next 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
none
-
Rhea-AI Summary

Phibro Animal Health (Nasdaq: PAHC) expects to announce its first quarter results on Wednesday, November 5, 2025 after market close. Management will host a conference call and webcast on Thursday, November 6, 2025 at 9:00 AM Eastern Time.

Investors can access the live presentation and slides at https://investors.pahc.com or dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) and provide conference ID 3927884. A replay of the webcast will be available approximately two hours after the live event at https://investors.pahc.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.63%
Tags
conferences earnings date
Rhea-AI Summary

Phibro Animal Health (Nasdaq: PAHC) announced on October 9, 2025 an exclusive licensing agreement with Lighthouse Pharmaceuticals to develop, manufacture, and commercialize a proprietary compound for canine periodontal health. Phibro will lead global regulatory, commercial, and distribution efforts while Lighthouse advances its gingipain inhibitor platform. The compound has shown preclinical efficacy and safety. Financial terms were not disclosed. The collaboration targets improved veterinary periodontal care and potential long‑term benefits for dogs and companion animal portfolios.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.10%
Tags
none
-
Rhea-AI Summary

Phibro Animal Health Corporation (Nasdaq: PAHC) announced its participation in the upcoming Morgan Stanley Annual Global Healthcare Conference. CFO Glenn David will present to financial analysts and investors on September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel.

The presentation will be accessible via live audio stream on the company's investor relations website, with a replay available for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
conferences
-
Rhea-AI Summary

Phibro Animal Health (NASDAQ:PAHC) reported strong financial results for Q4 and fiscal year 2025, with significant growth across key metrics. The company achieved Q4 net sales of $378.7M (up 39%) and net income of $17.2M (up $16.5M), with diluted EPS of $0.42.

For FY2025, PAHC reported net sales of $1.29B (up 27%), net income of $48.3M, and adjusted EBITDA of $183.7M (up 65%). The growth was primarily driven by the successful integration of the Zoetis MFA portfolio and strong performance across Animal Health segments.

Looking ahead, PAHC provided FY2026 guidance with projected net sales of $1.43-1.48B and adjusted EBITDA of $225-235M, reflecting continued confidence in their growth trajectory.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.44%
Tags
Rhea-AI Summary

Phibro Animal Health Corporation (Nasdaq: PAHC) has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Wednesday, August 27, 2025, after market close. The company will host a conference call and webcast to discuss the results on Thursday, August 28, 2025, at 9:00 AM Eastern Time.

Investors can access the presentation through the company's investor relations website at https://investors.pahc.com or join via phone using the provided dial-in numbers. A replay of the webcast will be made available approximately two hours after the event concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.32%
Tags
conferences earnings date
-
Rhea-AI Summary

Phibro Animal Health Corporation (Nasdaq: PAHC) has announced a quarterly dividend declaration. The company's Board of Directors has approved a cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on September 24, 2025, to shareholders who are registered as of September 3, 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.32%
Tags
dividends
-
Rhea-AI Summary

Phibro Animal Health Corporation (NASDAQ: PAHC) has announced its participation in the upcoming Stifel Jaws & Paws Conference. The company's Chief Operating Officer Larry Miller and Director and Executive Vice President of Corporate Strategy Daniel Bendheim will present to financial analysts and investors on Thursday, May 29, 2025, at 8:35 AM ET at the Lotte New York Hotel. The presentation will be accessible via live audio stream on Phibro's investor relations website, with a replay available for later viewing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.96%
Tags
conferences
Rhea-AI Summary
Phibro Animal Health Corporation (PAHC) reported strong Q3 FY2025 financial results, with net sales increasing 32% to $347.8 million and net income rising to $20.9 million. The company's performance was driven by the successful integration of the Zoetis MFA business and Phibro Forward initiatives. The Animal Health segment grew 42%, with MFA & Other product sales up 68%. The company updated its FY2025 guidance, projecting net sales of $1.26-1.29 billion and adjusted EBITDA of $177-183 million. Gross profit increased 31% to $104.6 million, while adjusted EBITDA rose 85% to $54.9 million. The company maintains a strong balance sheet with a 3.0x gross leverage ratio and $70.4 million in cash and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.75%
Tags

FAQ

What is the current stock price of Phibro Animal Health (PAHC)?

Phibro Animal Health (PAHC) last closed at $35.02.

What is the market cap of Phibro Animal Health (PAHC)?

The market cap of Phibro Animal Health (PAHC) is approximately $1.4B.